title: Cyclic 3',5'-guanosine monophosphate synthesis induced by atrial natriuretic peptide, C-type natriuretic peptide, and nitric oxide in the rat retina.
abstract: This study was undertaken to determine whether pathways exist in the rat retina for atrial natriuretic peptide (ANP)-, C-type natriuretic peptide (CNP)-, and nitric oxide (NO)- cyclic 3', 5'-guanosine monophosphate (cGMP). Exposure of the retina to ANP (10(-7) mol/L), CNP (10(-7) mol/L), S-nitroso-N-acetylpenicillamine (10(-5) mol/L, SNAP; a NO donor), A23187 (10(-5)mol/L; a Ca2+ ionophore), and carbachol (10(-3) mol/L) caused 1.45 approximately 1.67-fold increases in cGMP content (P < .01). The increase in cGMP content induced by A23187 was blocked by 2-4-carboxyphenyl . 4455-tetramethyl imidazoline 1-oxyl 3-oxide (10(-3) mol/ L, carboxy-PTIO; a NO scavenger). Both carboxy-PTIO (10(-3) mol/L) and NG-nitro-L-arginine (10(-3) mol/L, L-NNA: a NO synthase inhibitor) blocked the increase in cGMP content induced by carbachol. Atropine (10(-50 mol/L; a muscarinic receptor antagonist) also blocked the cGMP increase induced by carbachol. These data demonstrate that ANP-, CNP-, and NO-cGMP pathways exist in the rat retina and that the NO-cGMP pathway may be linked to the activation of the muscarinic receptor.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Tottori University, Yonago, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Moriwaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kamisaki
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: M
authors.initials: M
authors.lastname: Nagata
authors.forename: A
authors.initials: A
authors.lastname: Tamai
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000494:pharmacology; D006152:Cyclic GMP / Q000096:biosynthesis*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D016202:N-Methylaspartate / Q000494:pharmacology; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology*; D009569:Nitric Oxide / Q000494:pharmacology*; D019335:Nitroarginine / Q000494:pharmacology; D010396:Penicillamine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012160:Retina / Q000187:drug effects* / Q000378:metabolism
chemical_list: D001565:Benzoates; D018679:Cholinergic Agonists; D004791:Enzyme Inhibitors; D018690:Excitatory Amino Acid Agonists; D007093:Imidazoles; D007476:Ionophores; D018727:Muscarinic Antagonists; C110881:S-nitro-N-acetylpenicillamine; D020098:Natriuretic Peptide, C-Type; C079393:1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole; D019335:Nitroarginine; D009569:Nitric Oxide; D000001:Calcimycin; D016202:N-Methylaspartate; D001285:Atropine; D009320:Atrial Natriuretic Factor; D002217:Carbachol; D010396:Penicillamine; D006152:Cyclic GMP